Depletion of florfenicol amine in tilapia (Oreochromis sp.) maintained in a recirculating aquaculture system following Aquaflor®-medicated feed therapy

Aquaflor((R)) [50%ww(-1) florfenicol (FFC)], is approved for use in freshwater-reared warmwater finfish which include tilapia Oreochromis spp. in the United States to control mortality from Streptococcus iniae. The depletion of florfenicol amine (FFA), the marker residue of FFC, was evaluated after feeding FFC-medicated feed to deliver a nominal 20mg FFCkg(-1)BWd(-1) dose (1.33x the label use of 15mg FFCkg(-1)BWd(-1)) to Nile tilapia O. niloticus and hybrid tilapia O. niloticusxO. aureus held in a recirculating aquaculture system (RAS) at production-scale holding densities. Florfenicol amine concentrations were determined in fillets taken from 10 fish before dosing and from 20 fish at nine time points after dosing (from 1 to 240h post-dosing). Water samples were assayed for FFC before, during and after the dosing period. Parameters monitored included daily feed consumption and biofilter function (levels of ammonia, nitrite and nitrate). Mean fillet FFA concentration decreased from 13.77gg(-1) at 1-h post dosing to 0.39gg(-1) at 240-h post dosing. Water FFC concentration decreased from a maximum of 1400ngmL(-1) at 1day post-dosing to 847ngmL(-1) at 240h post-dosing. There were no adverse effects noted on fish, feed consumption or biofilter function associated with FFC-medicated feed administration to tilapia.